Surbhi Grover1,2,3, Priyanka Mehta4, Qiao Wang5, Rohini Bhatia6, Memory Bvochora-Nsingo7, Sonya Davey8, Meera Iyengar4, Sidrah Shah4, Sanghyuk S Shin2, Nicola M Zetola1. 1. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA. 2. Botswana-UPenn Partnership, Gaborone, Botswana. 3. Princess Marina Hospital, Gaborone, Botswana. 4. University of Texas Southwestern Medical Center, Dallas, TX. 5. University of California Irvine, Sue & Bill Gross School of Nursing, Irvine, CA. 6. Sinai Hospital of Baltimore, Baltimore, MD. 7. Gaborone Private Hospital, Gaborone, Botswana; and. 8. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Abstract
BACKGROUND: In Botswana, nearly two-thirds of cervical cancer patients are HIV-positive. This study examined the relationship between CD4 count and chemoradiation therapy outcomes among cervical cancer patients with HIV. SETTING: A prospective cohort study of 231 HIV-positive women with locally invasive cervical cancer was conducted in Gaborone, Botswana from January 2015 to February 2018. METHODS: Primary outcome was survival, defined as time from scheduled end of chemoradiation therapy to death or last contact with patient. Nadir CD4 count was defined as lowest CD4 available before cancer diagnosis. Delta CD4 count was defined as improvement from nadir CD4 to CD4 at cancer diagnosis. Hazard ratio (HR) analyses were adjusted for presenting variables (age, baseline hemoglobin, cancer stage, and performance status) and treatment variables (chemotherapy cycles and radiation dose). RESULTS: Two hundred thirty-one patients were included in nadir CD4 analysis; 139 were included in delta CD4 analysis. Higher delta CD4 was significantly associated with reduced mortality after adjusting for presenting and treatment variables (CD4 100-249: HR 0.45, 95% CI: 0.21 to 0.95; CD4 ≥250: HR 0.45, 95% CI: 0.20 to 1.02). Higher nadir CD4 showed a trend toward reduced mortality after adjusting for presenting and treatment variables (HR 0.94, 95% CI: 0.84 to 1.06). CONCLUSIONS: Higher delta CD4 (greater improvement from nadir CD4 to CD4 at cervical cancer diagnosis) is significantly associated with lower mortality. Although not statistically significant, data suggest that higher nadir CD4 may reduce mortality. These results reinforce the importance of early HIV diagnosis and antiretroviral therapy initiation, as their effects influence cervical cancer outcomes years later.
BACKGROUND: In Botswana, nearly two-thirds of cervical cancer patients are HIV-positive. This study examined the relationship between CD4 count and chemoradiation therapy outcomes among cervical cancer patients with HIV. SETTING: A prospective cohort study of 231 HIV-positive women with locally invasive cervical cancer was conducted in Gaborone, Botswana from January 2015 to February 2018. METHODS: Primary outcome was survival, defined as time from scheduled end of chemoradiation therapy to death or last contact with patient. Nadir CD4 count was defined as lowest CD4 available before cancer diagnosis. Delta CD4 count was defined as improvement from nadir CD4 to CD4 at cancer diagnosis. Hazard ratio (HR) analyses were adjusted for presenting variables (age, baseline hemoglobin, cancer stage, and performance status) and treatment variables (chemotherapy cycles and radiation dose). RESULTS: Two hundred thirty-one patients were included in nadir CD4 analysis; 139 were included in delta CD4 analysis. Higher delta CD4 was significantly associated with reduced mortality after adjusting for presenting and treatment variables (CD4 100-249: HR 0.45, 95% CI: 0.21 to 0.95; CD4 ≥250: HR 0.45, 95% CI: 0.20 to 1.02). Higher nadir CD4 showed a trend toward reduced mortality after adjusting for presenting and treatment variables (HR 0.94, 95% CI: 0.84 to 1.06). CONCLUSIONS: Higher delta CD4 (greater improvement from nadir CD4 to CD4 at cervical cancer diagnosis) is significantly associated with lower mortality. Although not statistically significant, data suggest that higher nadir CD4 may reduce mortality. These results reinforce the importance of early HIV diagnosis and antiretroviral therapy initiation, as their effects influence cervical cancer outcomes years later.
Authors: J M Palefsky; H Minkoff; L A Kalish; A Levine; H S Sacks; P Garcia; M Young; S Melnick; P Miotti; R Burk Journal: J Natl Cancer Inst Date: 1999-02-03 Impact factor: 13.506
Authors: Antonia L Moore; Caroline A Sabin; Sara Madge; Amanda Mocroft; Wendy Reid; Margaret A Johnson Journal: AIDS Date: 2002-04-12 Impact factor: 4.177
Authors: F B Lillo; D Ferrari; F Veglia; M Origoni; M A Grasso; S Lodini; E Mastrorilli; G Taccagni; A Lazzarin; C Uberti-Foppa Journal: J Infect Dis Date: 2001-08-09 Impact factor: 5.226
Authors: Lyle R McKinnon; Makobu Kimani; Charles Wachihi; Nico J Nagelkerke; Festus K Muriuki; Anthony Kariri; Richard T Lester; Lawrence Gelmon; T Blake Ball; Francis A Plummer; Rupert Kaul; Joshua Kimani Journal: PLoS One Date: 2010-07-02 Impact factor: 3.240
Authors: Tendani Gaolathe; Kathleen E Wirth; Molly Pretorius Holme; Joseph Makhema; Sikhulile Moyo; Unoda Chakalisa; Etienne Kadima Yankinda; Quanhong Lei; Mompati Mmalane; Vlad Novitsky; Lillian Okui; Erik van Widenfelt; Kathleen M Powis; Nealia Khan; Kara Bennett; Hermann Bussmann; Scott Dryden-Peterson; Refeletswe Lebelonyane; Shenaaz El-Halabi; Lisa A Mills; Tafireyi Marukutira; Rui Wang; Eric J Tchetgen Tchetgen; Victor DeGruttola; M Essex; Shahin Lockman Journal: Lancet HIV Date: 2016-03-24 Impact factor: 12.767
Authors: Nonhlanhla N Nkwanyana; Pamela P Gumbi; Lindi Roberts; Lynette Denny; Willem Hanekom; Andreia Soares; Bruce Allan; Anna-Lise Williamson; David Coetzee; Abraham J Olivier; Wendy A Burgers; Jo-Ann Passmore Journal: Immunology Date: 2009-03-26 Impact factor: 7.397
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Katharine A Rendle; Doreen Ramogola-Masire; Barati Monare; Shannon N Ogden; Hannah K Toneff; Chelsea A Saia; Jocelyn V Wainwright; Tara M Friebel-Klingner; Lisa Bazzett-Matabele; Rohini Bhatia; Natalie Bonner; Tlotlo B Ralefala; Peter Vuylsteke; Rebecca Luckett; Surbhi Grover Journal: BMC Womens Health Date: 2022-05-28 Impact factor: 2.742